David
Co-Founder
Jennifer recently asked our panel of experts:
Dr. Andrew Tinsley, M.D. of the Penn State Hershey Inflammatory Bowel Disease Center took time out of his busy schedule to answer this question. A little about Dr. Tinsley:
Dr. Andrew Tinsley was born and raised in England but attended medical school at the University of Vermont in Burlington. Following graduation from medical school, he completed internship and Residency in Internal Medicine at Massachusetts General Hospital / Harvard Medical School. He then entered a Gastroenterology Fellowship at Mount Sinai School of Medicine, NYC. While there, he was mentored there by Dr. Bruce Sands and received his IBD training from the likes of Asher Kornbluth, David Sachar, Thomas Ullman and John Fred Colombel. He was the Chief GI Fellow at Sinai in 2011-2012 and, while in New York, he also received a Masters in Biostatistics from Columbia University.
Currently, Dr. Tinsley is an Assistant Professor of Medicine at Penn State Hershey and Associate Director of the IBD Center there. In addition to seeing patients at the IBD Center, he carries out clinical research related to Crohn's disease and ulcerative colitis. His focus is on optimizing current treatment strategies and improving patient outcomes. Dr. Tinsley is a member of the CCFA and is fortunate to be part of a their IBD quality of care committee.
In regards to the question, Dr. Tinsley stated:
Thank you to Dr. Tinsley for his time and expertise!
Does use of steroids in Crohn's disease increase the chance of perforation, fistulae, and/or other complications? A medical doctor who posted once on our forum stated,
Doctor said:Steroids should be avoided if it is Crohn's as it promotes perforation and fistulization. I always tell my Crohn's patients that 9 out of ten times, you will get a Crohn's patient better with steroids at the cost of a ton of side-effects; however, nine out of 10 patients with complications were on steroids.
Dr. Andrew Tinsley, M.D. of the Penn State Hershey Inflammatory Bowel Disease Center took time out of his busy schedule to answer this question. A little about Dr. Tinsley:
Dr. Andrew Tinsley was born and raised in England but attended medical school at the University of Vermont in Burlington. Following graduation from medical school, he completed internship and Residency in Internal Medicine at Massachusetts General Hospital / Harvard Medical School. He then entered a Gastroenterology Fellowship at Mount Sinai School of Medicine, NYC. While there, he was mentored there by Dr. Bruce Sands and received his IBD training from the likes of Asher Kornbluth, David Sachar, Thomas Ullman and John Fred Colombel. He was the Chief GI Fellow at Sinai in 2011-2012 and, while in New York, he also received a Masters in Biostatistics from Columbia University.
Currently, Dr. Tinsley is an Assistant Professor of Medicine at Penn State Hershey and Associate Director of the IBD Center there. In addition to seeing patients at the IBD Center, he carries out clinical research related to Crohn's disease and ulcerative colitis. His focus is on optimizing current treatment strategies and improving patient outcomes. Dr. Tinsley is a member of the CCFA and is fortunate to be part of a their IBD quality of care committee.
In regards to the question, Dr. Tinsley stated:
In general, I try to minimize (or avoid altogether) the use of systemic steroids (i.e. prednisone) in Crohn’s patients if at all possible. This is based on current guidelines, clinical observations and teaching I received during my inflammatory bowel training at Mount Sinai. There are many reasons for this approach. The first is that, while steroids can lead to short-term disease improvement, they do not appear to be able to fully heal intestinal tissue over time (also known as mucosal healing). The ability of a Crohn’s medication to achieve mucosal healing is being increasingly recognized as an important treatment goal.
In contrast, other therapies such as azathioprine, mercaptopurine and biologics have been shown to accomplish this objective. While I am not aware of any specific research studies that prove that steroids actually promote perforation or fistula formation directly, these complications are more likely to happen when inflammation is not being fully treated and continues unchecked over time (despite many patients feeling better from a symptom standpoint). If a patient is found to have fistulizing Crohn’s disease, I avoid steroids altogether as they have never been shown to be effective in healing fistulas.
In addition, long-term steroid use can lead to other significant side-effects and complications. These complications include bone mineral density loss and risk for osteoporosis, avascular necrosis of the hip, glaucoma, hypertension, weight-gain, hyperglycemia, impaired wound-healing, increased risk of infections, as well as both sleep and mood problems. Along with narcotic use, long-term steroids are the only medications that have been shown to be associated with mortality in inflammatory bowel disease patients. Unfortunately, I often see patients who have been exposed to months and years of steroid use because of fear (by patients and/or providers) of potential side effects of other therapies. Using steroid-sparing medications such as azathioprine, mercaptopurine and biologics early in the disease course is a key strategy for effective and quality care for Crohn’s patients.
Thank you to Dr. Tinsley for his time and expertise!